Synthelabo's device sales up 5%:
This article was originally published in Clinica
Sales at Synthelabo's pacemaker division, Ela Medical, increased 5% to Fr627 million ($100 million) in 1997. During the year, the French company launched its dual chamber defibrillator, Defender II, in Europe. The product is in clinical trials in the US. Synthelabo's new pacemaker, Talent, is in clinical trials in Europe. The company recently announced a global co-marketing deal with US company Angeion (see Clinica No 778, p 7). Sales of the company's catheter division, Porges, rose 7% to Fr213 million.